Edition:
United Kingdom

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

651.70INR
7:33am GMT
Change (% chg)

Rs-4.25 (-0.65%)
Prev Close
Rs655.95
Open
Rs655.75
Day's High
Rs661.30
Day's Low
Rs651.35
Volume
338,633
Avg. Vol
988,188
52-wk High
Rs711.90
52-wk Low
Rs493.50

Latest Key Developments (Source: Significant Developments)

Glenmark Pharmaceuticals Enters Into Licensing Agreement With Yuhan Corp
Thursday, 10 Jan 2019 

Jan 10 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS ENTERS INTO AN EXCLUSIVE LICENSING AGREEMENT WITH YUHAN CORPORATION.DEAL WITH YUHAN CORP TO COMMERCIALIZE INVESTIGATIONAL SEASONAL ALLERGIC RHINITIS NASAL SPRAY RYALTRIS IN SOUTH KOREA.CO TO BE RESPONSIBLE FOR MANUFACTURING AND SUPPLY OF PRODUCT, WHILE YUHAN WILL BE RESPONSIBLE FOR REGULATORY FILING.CO WILL RECEIVE AN UPFRONT PAYMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS AS WELL AS ROYALTIES FROM YUHAN.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Fluocinolone Acetonide Oil
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS RECEIVES ANDA APPROVAL FOR FLUOCINOLONE ACETONIDE OIL, 0.01%.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Hydrocortisone Valerate Ointment
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS RECEIVES ANDA APPROVAL FOR HYDROCORTISONE VALERATE OINTMENT USP, 0.2%.  Full Article

Glenmark Pharmaceuticals Gets Tentative ANDA Nod For Clobetasol Propionate Foam, 0.05 Pct
Monday, 26 Nov 2018 

Nov 26 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS GETS TENTATIVE ANDA APPROVAL FOR CLOBETASOL PROPIONATE FOAM, 0.05%.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Atovaquone Oral Suspension USP, 750 Mg/5 Ml
Thursday, 22 Nov 2018 

Nov 22 (Reuters) - Glenmark Pharmaceuticals Ltd ::RECEIVES ANDA APPROVAL FOR ATOVAQUONE ORAL SUSPENSION USP, 750 MG/5 ML.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Azelaic Acid Gel, 15%
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS RECEIVES ANDA APPROVAL FOR AZELAIC ACID GEL, 15%.  Full Article

Glenmark Pharmaceuticals Launches Hair Growth Formula Nourkrin In Russia
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS LAUNCHES HAIR GROWTH FORMULA NOURKRIN IN RUSSIA.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Fluocinolone Acetonide Topical Oil
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS CO GETS ANDA APPROVAL FOR FLUOCINOLONE ACETONIDE TOPICAL OIL, 0.01% (SCALP OIL).  Full Article

Glenmark Pharmaceuticals Gets ANDA Nod For Fluocinolone Acetonide Topical Oil, 0.01 Pct
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Glenmark Pharmaceuticals Ltd ::GLENMARK PHARMACEUTICALS RECEIVES ANDA APPROVAL FOR FLUOCINOLONE ACETONIDE TOPICAL OIL, 0.01% (BODY OIL).  Full Article

Glenmark Pharmaceuticals Says Operations Committee Approves Launch Of FCC Bonds Buyback
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Glenmark Pharmaceuticals Ltd ::OPERATIONS COMMITTEE APPROVED LAUNCH OF BUYBACK OF FCC BONDS FROM EXISTING HOLDERS OF FCC BONDS.MUFG SECURITIES ASIA LIMITED AND J. P. MORGAN SECURITIES LIMITED ARE APPOINTED AS DEALER MANAGERS.APPROVED DEALER MANAGERS TO REPURCHASE FCC BONDS ON CO'S BEHALF FOR PURCHASE PRICE OF $100 MILLION PLUS INTEREST PER FCC BOND.  Full Article

Photo

Novartis's new treatment for hives outperforms Xolair in trials

ZURICH Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives.